Ardelyx, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-21$7.99 RISE2026-03-23$5.31 PEAK2026-05-04$7.30 103d | -33.5% 61d | Missed | Missed | — | — | +37.5% 42d | Missed |
DROP2026-01-21$7.99 RISE2026-03-20$5.31 PEAK2026-05-04$7.30 103d | -33.5% 58d | Missed | Missed | — | — | +37.5% 45d | Missed |
DROP2025-09-11$6.68 RISE2026-01-06$5.56 PEAK2026-01-21$7.99 132d | -16.8% 117d | Missed | Missed | — | — | +43.7% 15d | Missed |
DROP2025-09-11$6.68 RISE2025-10-10$4.94 PEAK2025-12-12$6.21 92d | -26.0% 29d | Missed | Missed | — | — | +25.7% 63d | Missed |
DROP2025-02-18$6.42 RISE2025-06-17$3.55 PEAK2025-09-11$6.68 205d | -44.7% 119d | Missed | Missed | — | — | +88.2% 86d | Missed |
DROP2025-02-18$6.42 RISE2025-05-14$3.28 PEAK2025-08-11$5.40 174d | -48.9% 85d | Missed | Missed | — | — | +64.6% 89d | Missed |
DROP2024-10-02$6.93 RISE2024-12-23$4.58 PEAK2025-02-18$6.42 139d | -33.9% 82d | Missed | Missed | — | — | +40.2% 57d | Missed |
DROP2024-10-02$6.93 RISE2024-11-13$4.50 PEAK2025-01-13$5.88 103d | -35.1% 42d | Missed | Missed | — | — | +30.7% 61d | Missed |
DROP2024-05-07$9.31 RISE2024-09-06$5.60 PEAK2024-10-02$6.93 148d | -39.8% 122d | Missed | Missed | — | — | +23.8% 26d | Missed |
DROP2024-02-27$9.67 RISE2024-07-02$5.28 PEAK2024-08-21$6.37 176d | -45.4% 126d | Missed | Missed | — | — | +20.6% 50d | Missed |
DROP2024-02-09$9.74 RISE2024-04-25$6.31 PEAK2024-05-07$9.31 88d | -35.2% 76d | Missed | Missed | — | — | +47.5% 12d | Missed |
DROP2023-09-12$4.83 RISE2023-10-12$3.29 PEAK2024-01-09$9.10 119d | -31.9% 30d | Missed | Missed | — | — | +176.6% 89d | Missed |
DROP2023-04-21$4.95 RISE2023-08-24$3.51 PEAK2023-09-12$4.83 144d | -29.1% 125d | Missed | Missed | — | — | +37.6% 19d | Missed |
DROP2023-04-21$4.95 RISE2023-07-03$3.30 PEAK2023-09-12$4.83 144d | -33.3% 73d | Missed | Missed | — | — | +46.4% 71d | Missed |
DROP2023-04-21$4.95 RISE2023-05-30$3.23 PEAK2023-06-13$4.06 53d | -34.7% 39d | Missed | Missed | — | — | +25.7% 14d | Missed |
1–15 / 26 1 / 2 | |||||||
No scored news yet for a sentiment trend.
We just covered the Claude Stock Portfolio: Top 10 Stocks to Buy According to AI Chatbot. Ardelyx Inc. (NASDAQ:ARDX) ranks #9 (see Claude Stock Portfolio: Top 5 Stocks to Buy According to AI Chatbot). Number of Hedge Funds: 30 Biotech company Ardelyx Inc. (NASDAQ:ARDX) is one of the recent additions in the Claude portfolio. Anthropic’s […]
In early May 2026, Ardelyx presented a new long-term analysis at the National Kidney Foundation meetings showing that XPHOZAH (tenapanor) reduced serum phosphate in chronic kidney disease patients on dialysis without clinically meaningful changes in other electrolytes, nutrition markers, body mass, or blood pressure, reinforcing its safety profile as an add-on therapy. The extended NORMALIZE and OPTIMIZE data, together with Ardelyx’s peer exchange on XPHOZAH’s first-in-class mechanism,...
Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and management's $1B revenue target by FY2029.
Ardelyx (ARDX) reported first quarter 2026 results, with revenue of US$94.47 million and a net loss of US$37.61 million, and reiterated full-year revenue guidance for IBSRELA and XPHOZAH. See our latest analysis for Ardelyx. Ardelyx’s latest earnings release and guidance update come after a strong 1 year total shareholder return of 91.89%, while the 30 day share price return of 18.93% suggests momentum has picked up again around US$7.10. If this earnings driven move has you looking beyond...
XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in
WALTHAM, Mass., May 07, 2026 -- Ardelyx, Inc. , a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet...
It's been a pretty great week for Ardelyx, Inc. ( NASDAQ:ARDX ) shareholders, with its shares surging 16% to US$6.88 in...
Ardelyx Inc (ARDX) reports significant revenue increases for IBSRELA and XPHOZAH, while navigating operational challenges and investing in future growth.
Moby summary of Ardelyx, Inc.'s Q1 2026 earnings call
Michael Raab: Thank you. At Ardelyx, we are building an innovative pipeline of medicines for patients with unmet medical needs. As we build on this momentum, our focus is on executing on our four key priorities: accelerating the growth of Ibsrela, maintaining the Exposa momentum, building and expanding our pipeline, and delivering strong financial results.
Ardelyx (ARDX) delivered earnings and revenue surprises of -15.39% and +3.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (NASDAQ:ARDX) executives said the company entered 2026 with “another significant year of growth” underway, highlighting strong first-quarter demand for its IBS-C product IBSRELA and continued momentum for kidney disease drug XPHOZAH, while also advancing pipeline efforts aimed at expanding t
Presentation Operator MessageOperator Welcome to the Ardelyx First Quarter 2026 Earnings Call. [Operator Instructions] I would now like to turn the conference over to Lisa Caperelli, Senior Vice...
While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ardelyx reports Q1 revenue of $94.5M, beating estimates, driven by 58% IBSRELA growth. Net loss narrows as key drug momentum builds toward blockbuster status.
WALTHAM, Mass. — WALTHAM, Mass. — Ardelyx Inc. on Thursday reported a loss of $37.6 million in its first quarter. On a per-share basis, the Waltham, Massachusetts-based company said it had a...
Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.13) by 15.38 percent. This is a 11.76 percent increase over losses of $(0.17) per share from the
Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year IBSRELA Q1 2026 revenue growth of 58% year-over-year to $70.1 million; Reiterating guidance of $410-$430 million ...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ARDX | -12.21% | -6.65% | +3.60% | +64.58% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -15.18% | -0.93% | +7.05% | +51.89% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 13.60M | $81.49M | 0.00% | Added+14.2% | 2026-03-31 |
| TwoSigma | quant | 4.27M | $25.60M | 0.02% | Added+48.7% | 2026-03-31 |
| Citadel | multi-strat | 2.98M | $17.88M | 0.02% | Added+211.3% | 2026-03-31 |
| RenTech | quant | 1.27M | $7.62M | 0.01% | Trimmed-29.1% | 2026-03-31 |
| DEShaw | quant | 314.0K | $1.88M | 0.00% | Trimmed-77.8% | 2026-03-31 |
| FidelityFMR | fundamental | 126.3K | $756.57K | 0.00% | Trimmed-81.4% | 2026-03-31 |
| Wellington | fundamental | 95.2K | $570.15K | 0.00% | Trimmed-4.9% | 2026-03-31 |
| TRowePrice | fundamental | 293.7K | $1.76K | 0.00% | Added+25.3% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-03upcoming | -0.04 | — | — |
| 2026-04-30 | -0.14 | -0.15 | -5.00% |
| 2026-02-19 | 0.01 | — | -100.00% |
| 2025-10-30 | -0.07 | — | +100.00% |
| 2025-08-04 | -0.14 | -0.08 | +41.55% |
| 2025-05-01 | -0.07 | -0.17 | -126.67% |
| 2025-02-20 | — | 0.02 | +2802.70% |
| 2024-10-31 | -0.05 | — | +100.00% |
| 2024-08-01 | -0.11 | -0.07 | +37.36% |
| 2024-05-02 | -0.16 | -0.11 | +32.27% |
| 2024-02-22 | -0.09 | -0.12 | -27.74% |
| 2023-10-31 | -0.11 | 0.03 | +127.67% |
| 2023-08-02 | -0.11 | -0.08 | +29.97% |
| 2023-05-03 | -0.10 | -0.13 | -34.77% |
| 2023-03-02 | — | 0.06 | +2486.21% |
| 2022-11-03 | -0.17 | -0.14 | +15.55% |